Calmare Therapeutics (CTTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2011 | 12-2010 | 07-2010 | 07-2009 | 07-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 779 | 1,307 | 908 | 752 | 2,237 |
| Receivables | 43 | 25 | 3,537 | 200 | 120 |
| Inventories | 4,210 | 1,730 | 273 | N/A | N/A |
| TOTAL | $5,101 | $3,140 | $4,786 | $1,159 | $2,675 |
| Non-Current Assets | |||||
| PPE Net | 26 | 41 | 164 | 203 | 263 |
| Other Non-Current Assets | 17 | 15 | 0 | 40 | 173 |
| TOTAL | $43 | $56 | $164 | $243 | $436 |
| Total Assets | $5,145 | $3,196 | $4,950 | $1,402 | $3,111 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,989 | 1,255 | 1,046 | 353 | 680 |
| Accrued Expenses | 1,229 | 407 | 1,229 | 682 | 759 |
| Other current liabilities | 441 | 882 | N/A | N/A | N/A |
| TOTAL | $6,772 | $2,544 | $2,275 | $1,035 | $1,439 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 13 | N/A | N/A | N/A | N/A |
| TOTAL | $N/A | $N/A | $66 | $81 | $79 |
| Total Liabilities | $6,772 | $2,544 | $2,341 | $1,116 | $1,518 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 14,830 | 13,825 | N/A | N/A | N/A |
| Common Shares | 147 | 138 | 138 | 98 | 82 |
| Retained earnings | -46,606 | -43,010 | -40,470 | -37,762 | -34,282 |
| Other shareholders' equity | 0 | -22 | -564 | 0 | 0 |
| TOTAL | $-1,627 | $651 | $2,609 | $285 | $1,593 |
| Total Liabilities And Equity | $5,145 | $3,196 | $4,950 | $1,402 | $3,111 |